Aspalathin, a natural product with the potential to reverse hepatic insulin resistance by improving energy metabolism and mitochondrial respiration

PLoS One. 2019 May 2;14(5):e0216172. doi: 10.1371/journal.pone.0216172. eCollection 2019.

Abstract

Aspalathin is a rooibos flavonoid with established blood glucose lowering properties, however, its efficacy to moderate complications associated with hepatic insulin resistance is unknown. To study such effects, C3A liver cells exposed to palmitate were used as a model of hepatic insulin resistance. These hepatocytes displayed impaired substrate metabolism, including reduced glucose transport and free fatty acid uptake. These defects included impaired insulin signaling, evident through reduced phosphatidylinositol-4,5-bisphosphate 3-kinase/ protein kinase B (PI3K/AKT) protein expression, and mitochondrial dysfunction, depicted by a lower mitochondrial respiration rate. Aspalathin was able to ameliorate these defects by correcting altered substrate metabolism, improving insulin signaling and mitochondrial bioenergetics. Activation of 5'-adenosine monophosphate-activated protein kinase (AMPK) may be a plausible mechanism by which aspalathin increases hepatic energy expenditure. Overall, these results encourage further studies assessing the potential use of aspalathin as a nutraceutical to improve hepatocellular energy expenditure, and reverse metabolic disease-associated complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Blood Glucose / metabolism
  • Cell Line
  • Chalcones / metabolism
  • Chalcones / pharmacology*
  • Energy Metabolism / drug effects*
  • Glucose / metabolism
  • Hepatocytes / metabolism
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Insulin / metabolism
  • Insulin Resistance / physiology
  • Liver / metabolism
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Models, Biological
  • Palmitates / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects

Substances

  • Blood Glucose
  • Chalcones
  • Hypoglycemic Agents
  • Insulin
  • Palmitates
  • aspalathin
  • Proto-Oncogene Proteins c-akt
  • AMP-Activated Protein Kinases
  • Glucose

Grants and funding

This work was funded by the National Research Foundation (NRF) of South Africa (NRF/JSPS Scientific Cooperation grant number 75425 to E Joubert and Thuthuka Programme grant 80618 and 113674 to SE Mazibuko-Mbeje). Baseline funding from Biomedical Research and Innovation Platform of the South African Medical Research Council (SAMRC) is also acknowledged. The grant holders acknowledge that opinions, findings and conclusions or recommendations expressed in any publication generated by the NRF and SAMRC supported research are those of the authors, and that the NRF and SAMRC accepts no liability whatsoever in this regard. The funding bodies had no involvement in the following aspects: study design; collection, analysis and interpretation of data; writing of the manuscript; decision to publish the work.